Concepts represent early planning stages for program announcements, request for applications, or solicitations for
Fogarty Advisory Board input. Clearance of a concept by Fogarty's Advisory Board does not guarantee it will become an initiative.
Ecology and Evolution of Infectious Diseases (EEID) Program
Purpose: Continue FIC participation in the NIH-NSF
Ecology and Evolution of Infectious Diseases (EEID) research program by supporting and administering EEID awards relevant to FIC’s mission and by serving as the NIH lead for this multi-agency program that supports research on the ecological, evolutionary, and social drivers that influence the transmission dynamics of infectious diseases.
Background: Many infectious diseases of global health significance, including zoonotic, vectorborne and waterborne diseases, are poorly controlled using current tools in the context of changing environments (e.g. urbanization, climate change, deforestation), challenges with insecticide and drug resistance, increased population mobility, and complex transmission strategies. The disease challenges include old enemies such as dengue, Chagas, malaria, and schistosomiasis, and newly emerging/remerging diseases such as SARS, Ebola, Zika, and Nipah virus, among others. As recent outbreaks and the current COVID-19 pandemic have shown, there is a need for improved multidisciplinary, quantitative and qualitative approaches to understand, predict and control these diseases.
The Ecology and Evolution of Infectious Diseases (EEID) program is a unique long-standing multi-agency competitive research grant program. A significant collaboration between NIH and NSF, this partnership brings together the scientific expertise and resources of multiple U.S. and international agencies to foster a research community that addresses challenges at the interface of ecology and health. The program supports research on the ecological, evolutionary, and socio-ecological principles and processes that influence the transmission dynamics of infectious diseases. The intent is discovery of principles of infectious disease transmission and testing mathematical or computational models that elucidate infectious disease systems.
Since FY2000 the program has supported over 180 awards by all funding partners. FIC has supported 24 EEID awards which have involved over 20 low- and middle-income countries (LMICs) and yielded more than 700 publications to date. The program has resulted in direct applications of EEID research findings to several infectious disease control programs and it has launched a new generation of U.S. and international scientists with integrative and quantitative biological skills. FIC’s involvement in EEID is steering a network of nontraditional research partners (e.g., agriculture, environmental science, evolutionary biology, field ecology, and mathematical modeling) to consider the global health agenda. Many projects supported by the EEID program take a “One Health” approach, recognizing the interconnection between people, animals, plants, and their shared environment. The community of mathematical modelers developed through the EEID program has been able to respond quickly to analyze and interpret emerging infectious disease threats and inform decision making.
EEID competitions are run under NSF Program Announcements and are reviewed by joint NSF-NIH panels, led by NSF.
Prior FIC Initiative: Notice of NIH Participation:
NOT-TW-20-007, NSF Solicitation:
Overview of Proposed Program: FIC will continue to participate in the EEID program and to serve as NIH lead for this multi-agency program. Participation will continue as currently configured with the following modifications. FIC will focus its EEID investments on global health research projects that enhance research capacity in LMICs and that include LMIC investigators in leadership roles (e.g., key personnel on FIC awards). Accordingly, an updated FIC interest paragraph, articulating these priorities, will be included in the NSF solicitation.
Relevance to FIC Strategic Plan: The EEID program supports several of FIC’s strategic goals. The program builds research capacity to meet future and evolving global health challenges (Goal 1); projects focus on locally relevant solutions to address global health problems (Goal 2); many projects promote update of evidence into global health policy and practice (Goal 3); and the program fosters partnerships with LMIC researchers and research institutions (Goal 5).
Inquiries: Dr. Christine Jessup
Fogarty Global Health Training Program
Purpose: To foster the next generation of global health scientists in a broad range of scientific areas and build a network of global health researchers in the US and in low and middle income countries (LMICs) by giving investigators, early in their careers, a research experience in global health at well-established, internationally-funded research institutions in LMICs.
Background: This program started in 2004 as supplements to Fogarty International Center (FIC) training grants with some administrative support from the Ellison Foundation. The program was designed to encourage the next generation of clinical researchers to focus on international health issues by giving them hands-on experience conducting research in LMICs during the formative years of their medical training. In 2007, the program evolved into an independent five-year educational development program (the Fogarty International Clinical Research Training Program for Scholars and Fellows, FICRS-F) and was expanded to include medical residents and fellows and PhD scientists with interest in health-related research. Since the FICRS-F, the program was restructured and reissued in 2012 as the
Global Health Program for Fellows and Scholars (R25) and reissued again in 2017 as an international research training grant (D43).
Collectively, these programs have supported one-year mentored research training to over 1300 pre- and post-doctoral trainees and other health-related professional participants, whose research experiences have led to over 2,400 peer-review publications in a wide variety of infectious, including HIV/AIDS, and non-communicable disease areas. In the current program, five-year awards were made to six (6) U.S. consortia to support research training at over 133 collaborating institutions in 41 LMICs. Each consortium is composed of four (4) US universities, with a minority-serving institution as a consortium or recruitment partner, and several LMIC partners. The consortia draw students from their own institutions and from collaborating LMIC research institutions.
The program began with only Fogarty support but has since grown to include partnerships with and ad hoc support from many NIH Institutes, Centers, and Offices. In the current round of the program, these have included FIC, NIMH, NINDS, NHLBI, OD/ORWH, OD/OAR, OD/OBSSR, NCI, NEI, NIAMS, NIBIB, NICHD, NIDCD, NIDCR, NIDDK, NIEHS, and NINR.
Prior FIC Initiative:
Overview of Proposed Program: For the next cycle, the program will retain many of the characteristics of the current program, such as the consortium model, support of projects in a wide variety of research areas, and encouraged cross-network activities among awardees. A prominent aspect of the reissued program will be strong encouragement of greater outreach to, recruitment of, and participation by underrepresented minorities to help diversify the global health workforce and thereby accelerate our understanding and development of solutions to address global health challenges. See the related November 2019
Notice of NIH's Interest in Diversity (NOT-OD-20-031). However, a significant proposed change to the program is the support of only US and LMIC postdoctoral/post-professional degree trainees, as the program is expected to have a greater impact on more scientifically mature and independent investigators. US pre-doctoral students may continue to participate in the program through the Fulbright-Fogarty Fellowship Program. In addition, LMIC trainees will be expected to undertake a short (2- to 3-month) training experience at a US site. This opportunity will allow LMIC trainees to gain new skills, meet current and future US collaborators, experience the challenges of working in an unfamiliar scientific and national culture, as well as give them greater exposure to research in the US.
Relevance to FIC Strategic Plan: The Fogarty Global Health Research Training Program supports FIC’s strategic goals by building future research leaders in the U.S. and low- and middle-income countries (LMIC; Goal 1), supporting projects focused on locally relevant solutions to address global health problems (Goal 2), and fostering partnerships with LMIC researchers and research institutions (Goal 5).
Inquiries: Dr. UnJa Hayes
Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle- Income Countries
Purpose/Goals and Objectives: To develop and/or pilot test interventions for HIV/AIDS-associated stigma and its outcome on the prevention and treatment of HIV/AIDS and on the quality of life of People Living with HIV/AIDS (PLWH). Specifically, this initiative will support research on or leading to interventions to address a) innovation in measurement of HIV-associated stigma and of other intersecting stigmas due to multiple morbidities to develop better interventions, b) stigma and adolescent and/or youth health, c) effects of stigma on family members or care givers of PLWH, and on the aging PLWH, d) novel stigma reduction interventions that link to increase in care-seeking behavior and/or decrease in transmission and e) coping with the complexity of added burden of stigmatization due to HIV and to one or more comorbidities/coinfections.
Background/Rationale: Despite significant advances in biomedical approaches to prevent HIV transmission, acquisition of new infections has not abated, suggesting the need for further research into the possible causes of and new ways to mitigate the spread of the disease. The role of stigma is implicated in resurgence of new infections via continued transmission. HIV-associated stigma has been a barrier to getting tested and treated, especially in Low- and Middle-Income Countries (LMICs). Adolescents and youth are particularly vulnerable and their unique psychological and physiological features to deal with stigma-related stress have not been well studied. Exposed but uninfected people can be the targets of stigma that can affect their health in different ways, especially children of infected parents and caregivers. There is also a need for better stigma measures that can help in assessing the efficacy of stigma reduction interventions at different stages.
Prior/Current Related FIC and other NIH Initiatives: The Fogarty International Center (FIC) convened an international conference on Stigma and Global Health in 2001, followed by issuance of an FOA from which 19 awards were made in 2003 by FIC and 11 other partners at NIH, HRSA, CIHR, and IDRC [RFA-TW-03-001; see also
2006 Lancet supplement based on these awards; and
independent review of the program]. These grants covered a wide range of topics for work in both US and LMIC institutions and only four concerned Stigma and HIV/AIDS. Two other NIH initiatives addressing stigma were a series of PAs issued in 2013, from which eight awards were made, and an RFA for competitive supplements from NIMH in 2014 focusing on HIV, from which only 2 grants were awarded, one of which was for work in an LMIC. The paucity of funded HIV associated stigma grants in the LMICs spurred FIC to initiate a new program,
Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries, in 2017. In 2019 NIMH issued three RFAs to investigate reducing intersectional stigma using the R01, R34 and R21 mechanisms, which was also specifically focused on defined PLWH populations. Over the last four years FIC has
awarded 27 grants from 18 different countries working on various stigma manifestations and focused on a number of different approaches and research topics. These programs have built the foundation and the momentum for conducting HIV-associated stigma research in LMICs. We now propose to expand the program by providing additional time and funds to explore effective interventions with the potential for implementation and scale up.
Prior FIC Initiative: PAR-19-326
Overview of Proposed Program: Through this initiative, FIC encourages new research to investigate the aspects of stigma that continue to hinder progress towards HIV prevention, treatment, and care in LMICs, and to develop and/or pilot test appropriate interventions for stigma reduction. The initiative encourages research to reduce the impact of stigma at the individual, community, health care system, and policy levels. Applicants will be asked to address the ability of collaborating LMIC institutions to develop and sustain capacity for carrying out research in this field. Research teams should contain an appropriate mix of disciplines to accomplish the proposed studies. The initiative will use a research grant mechanism (small R01) with approximately $400K total funds divided over a 3-year period. Applicants should develop their studies in keeping with the
NIH and OAR priorities for HIV research.
Relevance to FIC Strategic Plan: The proposed initiative supports several of FIC’s strategic goals. It will build research capacity through individuals, institutions, and networks to meet future and evolving global health challenges (Goal 1). It stimulates innovation in the development and implementation of technologies and other locally relevant solutions to address global health problems (Goal 2). It advances research on prevention and control of the dual burden of communicable and noncommunicable diseases and disabilities (Goal 4). It builds and strengthens partnerships to advance global health research and research capacity (Goal 5)
Eligibility: US and LMIC investigators for work to be done in partnership at LMIC institutions or sites. Where possible, an LMIC investigator is encouraged to be the contact PI or MPI. Both north-south and south-south collaborations are encouraged.
Inquiries: Dr. Geetha P. Bansal
Global Infectious Disease Research Training Program (D43)
For the published request for applications, see the NIH Guide announcement
Global Infectious Disease Research Training Program (D43 Clinical Trial Optional) (PAR-20-229), published June 10, 2020.
Reissue Global Brain and Nervous System Disorders Research across the Lifespan (GLOBAL BRAIN) FOAs (R21, R01)
Global BRAIN program was established in 2002 to address the burden of neurological disorders across the lifespan in low- and middle-income countries (LMICs). The program is configured as two related trans-NIH announcements, a R21 planning/exploratory grant and a R01 application to a partner IC. As of 2018, 165 R21s and 61 R01s representing 41 LMICs were awarded. The current FOAs have one more 2019 receipt date. We propose to reissue program FOAs for another three years starting in 2020.
- Support research on nervous system development, function, health and impairment (neuro-health) at any life stage or across the lifespan on topics relevant to LMICs;
- Build neuro-health research capacity among LMIC partners and institutions involved in a specific research project;
- Encourage initiatives that lead to appropriate and innovative diagnostics, prevention, and treatment strategies;
- Encourage collaboration among LMIC institutions;
- Promote career development of young LMIC investigators in neuro-health related research.
Eligibility: Domestic and foreign institutions are eligible to apply for both the R21 and R01 FOAs. Applications must be submitted as collaborations between institutions in at least 2 different countries: a U.S. OR an Upper-Middle Income Country (UMIC) with a LMIC (including UMIC-UMIC collaborations). The R01 is intended to provide an investigator with the opportunity to further develop collaborative pilot research conducted in the LMIC countr(ies), so the scientist submitting an R01 may either have a previous R21 under this program or alternatively, show strong evidence of an ongoing research collaboration with strong global health infrastructure being developed at the LMIC institution(s). Furthermore, the research proposed in the R01 must coincide with the research interests of a participating partner organization or partner NIH IC, as FIC co-funds but does not routinely award the R01.
Priority Areas: Target research areas include broadly nervous system function, behavior, neuro-health and disease across the lifespan, including for example, neurological, neuropsychiatric, addictive, neuro-developmental and neurodegenerative diseases and disorders; and topics of special relevance in LMICs such as neuro-infectious diseases, neuro-trauma and seizure disorders. Research may cover impacts on individuals or populations at a certain life stage or across the lifespan. Researchers focusing on genetic, epigenetic and environmental drivers, factors that affect healthy brain development and aging, health care delivery, and socio-economic factors are also encouraged. Applications may focus across the spectrum of research types: basic, epidemiological, clinical, health services, translational and implementation research. Lab, human, animal and population-based studies are all accepted. As an option, applicants are also encouraged to leverage research collaboration networks within a specific diseases or disorder-related topical area to build enhanced in-country and regional research capacity.